Pediatric Oncall Home
Doctor Corner Home
Parent Corner Home
Child Corner Home
Diseases and Conditions
Ask the Expert
Question of the Day
Online CME Center
Common Child Diseases
Diet and Diseases
Home Made Remedies
Know Your Body
Why What How
ISSN 0973 - 0958
Search From :
New user Register
User name :
Swine Flu Center
Lab confirmation and infection control in novel influenza A (H1N1)
Follow Us :
Designated hospitals for isolation and treatment of swine flu patients
How to isolate a patient with swine flu
How to suspect swine flu
Infection Control Practices in Health Care Settings
When to test for H1N1 Influenza
Testing for swine flu
Laboratory Confirmation and Infection control in novel Influenza (H1N1)
Treatment of the new HINI flu virus
You are welcome to ask your own query
LABORATORY CONFIRMATION AND INFECTION CONTROL IN NOVEL INFLUENZA A (H1N1)
Haffkine Institute, Parel, Mumbai
Address for Correspondence:
Prof Abhay Chowdhary (MD, DHA, DM Virology, FIMSA), Director, Haffkine Institute, Parel, Mumbai 400012.
firstname.lastname@example.org ; email@example.com
Human cases of novel influenza A (H1N1) virus infection have been confirmed in people all over the world. WHO declared the pandemic Investigations of these cases suggest that on-going human-to-human novel H1N1 virus is occurring. Illness signs and symptoms have consisted of
fever and respiratory tract illness (cough, sore throat, runny nose),
, muscle aches, Some cases have had vomiting and diarrhea. Cases of severe respiratory disease, including fatal outcomes, have been reported.
The novel H1N1 virus that has infected humans all over the world is a novel influenza A virus that is resistant to the antiviral medications amantadine and rimantadine but is sensitive to oseltamivir and zanamivir.
of novel influenza A (H1N1) virus infection is defined as a person with an influenza-like illness with laboratory confirmed novel influenza A (H1N1) virus infection by one or more of the following tests:1.
real-time RT-PCR 2. viral culture.
Duration of viral shedding
The duration of shedding with novel influenza A (H1N1) virus is unknown. Therefore, until data are available, the estimated duration of viral shedding is based upon seasonal influenza virus infection. Infected persons are assumed to be shedding virus and potentially infectious from the day prior to illness onset until resolution of
. Infected persons should be assumed to be contagious
up to 7 days
from illness onset. Some persons who are infected might potentially shed virus and be contagious for longer periods (e.g. young infants, immunosuppressed, and immunocompromised persons).
Testing for novel influenza A (H1N1) virus
Clinicians should consider testing suspected cases of novel influenza A (H1N1), especially those with severe illness, by obtaining an upper respiratory specimen to test for novel influenza A (H1N1) virus.
Preferred respiratory specimens
The following should be collected as soon as possible after illness onset: nasopharyngeal swab, nasal aspirate or a
combined nasopharyngeal swab
. If these specimens cannot be collected, a nasal swab or oropharyngeal swab is acceptable. For patients who are intubated, an endotracheal aspirate should also be collected.
Bronchoalveolar lavage (BAL) and sputum specimens are also acceptable. Specimens should be placed into sterile
viral transport media (VTM)
and immediately placed on ice or cold packs or at 4°C (refrigerator) for transport to the laboratory. Recommended infection control should be followed.
Ideally, swab specimens should be collected using swabs with a synthetic tip (e.g. polyester or Dacron®) and an aluminum or plastic shaft. Swabs with cotton tips and wooden shafts are not recommended. Specimens collected with swabs made of calcium alginate are not acceptable. The swab specimen collection vials should contain 1-3ml of viral transport medium (e.g. containing, protein stabilizer,
to discourage bacterial and fungal growth, and buffer solution).
Storing clinical specimens
All respiratory specimens should be kept at 4°C for no longer than 4 days.
Shipping clinical specimens
Clinical specimens should be shipped on wet ice or cold packs in appropriate packaging. All specimens should be labeled clearly and include information requested by your state public health laboratory. Suspected case specimens shipped from the state public health laboratory to CDC should include all information required for seasonal influenza surveillance isolate or specimen submission.
Real-time RT-PCR is the recommended test for confirmation of novel influenza A (H1N)1 cases. Currently, novel influenza A (H1N1) virus will test positive for influenza A and negative for H1 and H3 by real-time RT-PCR. If reactivity of real-time RT-PCR for influenza A is strong (e.g. Ct <30) it is more suggestive of a novel influenza A (H1N1) virus. Confirmation as novel influenza A (H1N1) virus by real-time RT-PCR was originally performed only at CDC, but at this time it is available in
Haffkine Institute, Mumbai, NIV, Pune, NICD, Delhi and few other laboratories.
Other tests for influenza
Rapid influenza antigen test
Some commercially available rapid tests can distinguish between influenza A and B viruses. A patient with a positive rapid test for influenza A may meet criteria for a suspected case of novel influenza A (H1N1) virus infection. However,
it is not possible to differentiate from seasonal influenza A viruses
. Also, these tests have unknown sensitivity and specificity to detect human infection with novel influenza A (H1N1) virus in clinical specimens, and have suboptimal sensitivity to detect seasonal
a negative rapid test could be a false negative and should not be assumed a final diagnostic test for novel influenza A (H1N1) virus infection.
Immunofluorescence (DFA or IFA)
These tests can distinguish between influenza A and B viruses. A patient with a positive for influenza A by Immunofluorescence may meet criteria for a suspected case. However, it is not possible to differentiate from seasonal influenza A viruses. Immunofluorescence depends upon the quality of a clinical specimen, operator skills, and has unknown sensitivity and specificity to detect human infection with novel influenza A (H1N1) virus in clinical specimens. Therefore, a negative Immunofluorescence could be a false negative and should not be assumed a final diagnostic test for novel influenza A (H1N1) virus infection.
Isolation of novel influenza A (H1N1) virus is diagnostic of infection, but may not yield timely results for clinical management hence not recommended. A negative viral culture does not exclude infection with novel influenza A (H1N1) virus. It is requires Bio Safety Level 3 facility.
CDC recommends that people with influenza-like illness remain at home until at least 24 hours after they are free of fever (100° F [37.8°C]), or signs of a fever without the use of fever-reducing medications.
This is a change from the previous recommendation that ill persons stay home for 7 days after illness onset or until 24 hours after the resolution of symptoms, whichever was longer. The new recommendation applies to camps, schools, businesses, mass gatherings, and other community settings where the majority of people are not at increased risk for influenza complications.
In India the behaviour of virus is very mild and is not of major concern. However due care must be ensured for children and elderly. The panic button need not be pressed yet.
Please remember, saying namaste with folded hands from a distance is a good age old Indian way to greet and avoid unnecessary contact with others.
How to Collect Throat and Nasal Swab
Swine Flu qustions related to isolation and quarantine
Prevention and prophylaxis
Testing for H1N1 influenza
Travel information and swine flu
Swine Flu - how dangerous is it?
Use of surgical masks to prevent H1N1 influenza
What is Swine flu?
Approach to Management of H1N1 Influenza
There Are No Videos Present.
Syrup formulations of antiretrovirals especially zidovudine and nevirapine are in short supply due to decreased production. How to give prophylaxis to the babies to prevent vertical transmission of HIV_?
Pulverise the adult tablet and give
Do not give prophylaxis to the babies
On humanitarian grounds, the production should be maintained
Terms & Condition
Link to Us
Pediatric oncall book store
Swine Flu Center
HIV in Children
Infection in Children
Pediatric Oncall Journal
Swine Flu Center
The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
Sitemap For Doctor
Sitemap For Parent
Sitemap For Kids
copyright ©2011 website design & development by
Follow us on :